List of Trokendi Xr drug patents

Trokendi Xr is owned by Supernus Pharms.

Trokendi Xr contains Topiramate.

Trokendi Xr has a total of 10 drug patents out of which 0 drug patents have expired.

Trokendi Xr was authorised for market use on 16 August, 2013.

Trokendi Xr is available in capsule, extended release;oral dosage forms.

Trokendi Xr can be used as use of trokendi xr for the treatment of epilepsy; use of trokendi xr for prophylactic treatment of migraine, use of trokendi xr for prophylactic treatment of migraine; use of trokendi xr for the treatment of epilepsy, use of trokendi xr for prophylactic treatment of migraine; treatment of epilepsy, treatment of epilepsy; use of trokendi xr for prophylactic treatment of migraine.

The generics of Trokendi Xr are possible to be released after 04 April, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314790 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9622983 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8663683 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8992989 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8889191 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9549940 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8298580 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8877248 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9555004 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8298576 SUPERNUS PHARMS Sustained-release formulations of topiramate
Apr, 2028

(5 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 16 August, 2013

Treatment: Use of trokendi xr for the treatment of epilepsy; Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of TROKENDI XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic